Literature DB >> 7607841

Phaeochromocytoma--a laboratory experience.

W P Tormey1, R J FitzGerald.   

Abstract

Thirteen phaeochromocytomas were found over five and a half years from 2,834 patient requests for tumour screens. HMMA (VMA) was the usual screening test requested. Free catecholamines were reported when specifically requested by clinicians and where the HMMA level was > 40 mumol/24 hr. HMMA and urinary free catecholamines were estimated using HPLC with electrochemical detection in acidified 24 hr collections. Noradrenaline was elevated in all thirteen, nine had raised adrenaline and two had raised levels of all three catecholamines. Urinary free catecholamines are the most appropriate analyte package in our circumstances for the diagnosis of phaeochromocytoma. HMMA if used alone could lead to false negative diagnoses but it has a role in minimising false negatives where urinary catecholamine results are normal.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7607841     DOI: 10.1007/BF02973282

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  29 in total

1.  Urinary catecholamine assay by HPLC: in vitro interference by some drugs.

Authors:  D F Davidson
Journal:  Ann Clin Biochem       Date:  1988-09       Impact factor: 2.057

2.  Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications.

Authors:  E L Bravo; R C Tarazi; R W Gifford; B H Stewart
Journal:  N Engl J Med       Date:  1979-09-27       Impact factor: 91.245

3.  A re-evaluation of dopamine excretion in phaeochromocytoma.

Authors:  P A Tippett; A J McEwan; D M Ackery
Journal:  Clin Endocrinol (Oxf)       Date:  1986-10       Impact factor: 3.478

4.  Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease.

Authors:  H P Neumann; D P Berger; G Sigmund; U Blum; D Schmidt; R J Parmer; B Volk; G Kirste
Journal:  N Engl J Med       Date:  1993-11-18       Impact factor: 91.245

5.  Interpretation of random urinary catecholamines and their metabolites in neuroblastoma.

Authors:  A O'Meara; W Tormey; R J FitzGerald; M Fitzgibbon; D Kenny
Journal:  Acta Paediatr       Date:  1994-01       Impact factor: 2.299

6.  Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion.

Authors:  C Proye; P Fossati; P Fontaine; J Lefebvre; M Decoulx; J L Wemeau; D Dewailly; E Rwamasirabo; P Cecat
Journal:  Surgery       Date:  1986-12       Impact factor: 3.982

7.  Phaeochromocytoma and catecholamine induced cardiomyopathy presenting as heart failure.

Authors:  S H Sardesai; A J Mourant; Y Sivathandon; R Farrow; D O Gibbons
Journal:  Br Heart J       Date:  1990-04

8.  Clinically unsuspected pheochromocytomas. Experience at Henry Ford Hospital and a review of the literature.

Authors:  N K Krane
Journal:  Arch Intern Med       Date:  1986-01

9.  [Screening for phaeochromocytoma : in which hypertensive patients? A semiological study of 2585 patients, including 11 with phaeochromocytoma (author's transl)].

Authors:  P F Plouin; P Degoulet; A Tugayé; M B Ducrocq; J Ménard
Journal:  Nouv Presse Med       Date:  1981-03-07

10.  Scintigraphic localization of pheochromocytoma.

Authors:  J C Sisson; M S Frager; T W Valk; M D Gross; D P Swanson; D M Wieland; M C Tobes; W H Beierwaltes; N W Thompson
Journal:  N Engl J Med       Date:  1981-07-02       Impact factor: 91.245

View more
  1 in total

1.  Lack of uniformity in the clinical approach to the interpretation of urinary catecholamines and their metabolites.

Authors:  W P Tormey; R J FitzGerald
Journal:  Ir J Med Sci       Date:  1995 Apr-Jun       Impact factor: 1.568

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.